Biotech Sidesteps Consolidation
Executive Summary
With top-tier biotechs uncertain where their follow-on products will come from, some industry executives are predicting a coming wave of consolidation. But for a variety of structural and managerial reasons, significant consolidation is unlikely. In particular, top-tier biotechs prefer in-licensing to the valuation and managerial headaches of mergers, while discovery companies question the logic of fully-integrated services.
You may also be interested in...
EU Medtech May Have Standards Certainty Days Before MDR Applies
The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last
Gilead Keeps Close Eye On Stormy Remdesivir Situation In India
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.
China Re-Infection Case Ignites Antibody Durability Debate
Amid a case of re-infection of a vaccinated healthcare worker in western China’s Xi’an city, and ongoing debate over domestic vaccines' efficacy, increasing attention is being paid in China to raising inoculation rates for COVID-19 and moving towards herd immunity.